The Deets In November 2024, the Biden administration proposed a major shift: allowing CMS to cover GLP-1s like Wegovy and Zepbound for obesity treatment
Clinical studies have demonstrated its effectiveness in not only reducing body weight but also improving several health markers associated with obesity, including blood sugar levels and cardiovascular risk factors
Clinical studies have also shown significant improvements in: In my practice, I have seen patients not only lose weight but also reduce their dependence on other medications for conditions like type 2 diabetes and high blood pressure
SCS includes low-frequency SCS (frequency 10100 Hz, pulse width 1001,000 ms, and amplitude 110 mA) that applies paresthesia-based stimulation and high-frequency SCS (frequency 110 kHz, pulse width 30150 ms, and amplitude 15 mA) that applies stimulation below the paresthesia threshold [96]
Previous strategies to overcome these barriers, including dose optimization, image-guided planning, and combination systemic therapy, have achieved only incremental gains, leaving a significant unmet clinical need for innovative, tumor-targeted solutions [18, 19]
